keyword
MENU ▼
Read by QxMD icon Read
search

Treatment of heart failure

keyword
https://www.readbyqxmd.com/read/29655829/renal-effects-and-associated-outcomes-during-angiotensin-neprilysin-inhibition-in-heart-failure
#1
Kevin Damman, Mauro Gori, Brian Claggett, Pardeep S Jhund, Michele Senni, Martin P Lefkowitz, Margaret F Prescott, Victor C Shi, Jean L Rouleau, Karl Swedberg, Michael R Zile, Milton Packer, Akshay S Desai, Scott D Solomon, John J V McMurray
OBJECTIVES: The purpose of this study was to evaluate the renal effects of sacubitril/valsartan in patients with heart failure and reduced ejection fraction. BACKGROUND: Renal function is frequently impaired in patients with heart failure with reduced ejection fraction and may deteriorate further after blockade of the renin-angiotensin system. METHODS: In the PARADIGM-HF (Prospective Comparison of ARNI with ACE inhibition to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial, 8,399 patients with heart failure with reduced ejection fraction were randomized to treatment with sacubitril/valsartan or enalapril...
April 5, 2018: JACC. Heart Failure
https://www.readbyqxmd.com/read/29655825/hypertrophic-cardiomyopathy-clinical-update
#2
REVIEW
Jeffrey B Geske, Steve R Ommen, Bernard J Gersh
Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, manifesting as left ventricular hypertrophy in the absence of a secondary cause. The genetic underpinnings of HCM arise largely from mutations of sarcomeric proteins; however, the specific underlying mutation often remains undetermined. Patient presentation is phenotypically diverse, ranging from asymptomatic to heart failure or sudden cardiac death. Left ventricular hypertrophy and abnormal ventricular configuration result in dynamic left ventricular outflow obstruction in most patients...
April 5, 2018: JACC. Heart Failure
https://www.readbyqxmd.com/read/29655822/clinical-spectrum-and-management-of-heart-failure-in-hypertrophic-cardiomyopathy
#3
REVIEW
Barry J Maron, Ethan J Rowin, James E Udelson, Martin S Maron
Heart failure (HF), characterized by excessive exertional dyspnea, is a common complication within the broad clinical spectrum of hypertrophic cardiomyopathy (HCM). HF has become an increasingly prominent management issue with the reduction in sudden deaths due to use of implantable defibrillators in this disease. Exertional dyspnea ranges in severity from mild to severe (New York Heart Association functional classes II to IV) and not uncommonly becomes refractory to medical management, leading to progressive disability, but largely in the absence of pulmonary congestion and volume overload requiring hospitalization...
April 5, 2018: JACC. Heart Failure
https://www.readbyqxmd.com/read/29655692/effects-of-xin-ji-er-kang-on-heart-failure-induced-by-myocardial-infarction-role-of-inflammation-oxidative-stress-and-endothelial-dysfunction
#4
Juan Hu, Pan Cheng, Guang-Yao Huang, Guo-Wei Cai, Feng-Zhen Lian, Xiao-Yun Wang, Shan Gao
BACKGROUND: Xin-Ji-Er-Kang (XJEK) is a Chinese herbal formula, which has been reported to exert effective protection on cardiovascular diseases like hypertension and myocarditis. PURPOSE: To elucidate the protective effects of XJEK on heart failure (HF) induced by myocardial infarction (MI) through the amelioration of inflammation, oxidative stress (OS) and endothelial dysfunction(ED). MATERIALS AND METHODS: Fifty-seven male KM mice were randomized into the following six groups (n = 9-10 for each): control group, model group, MI+XJEK low dose group(XJEKL) group, MI+XJEK middle dose group(XJEKM), MI+XJEK high dose group(XJEKH), and MI+fosinopril group (positive control group)...
March 15, 2018: Phytomedicine: International Journal of Phytotherapy and Phytopharmacology
https://www.readbyqxmd.com/read/29655477/cardiovascular-drugs-in-avian-small-mammal-and-reptile-medicine
#5
Brenna Colleen Fitzgerald, Sara Dias, Jaume Martorell
Cardiovascular disease, including congestive heart failure, pericardial disease, and atherosclerosis, is becoming increasingly better recognized in companion birds, small mammals, and reptiles. A wide range of medications is available to treat these conditions, including diuretics, vasodilators, positive and negative inotropes, antiarrhythmic agents, and pentoxifylline. This review systematically discusses each of these drug classes and their potential applications in exotic species. Although treatment approaches remain largely empirical and extrapolated from small animal and human medicine, the management strategies presented here have the potential to both maintain quality of life and extend survival time for the exotic cardiac patient...
May 2018: Veterinary Clinics of North America. Exotic Animal Practice
https://www.readbyqxmd.com/read/29653073/a-zebrafish-heart-failure-model-for-assessing-therapeutic-agents
#6
Xiao-Yu Zhu, Si-Qi Wu, Sheng-Ya Guo, Hua Yang, Bo Xia, Ping Li, Chun-Qi Li
Heart failure is a leading cause of death and the development of effective and safe therapeutic agents for heart failure has been proven challenging. In this study, taking advantage of larval zebrafish, we developed a zebrafish heart failure model for drug screening and efficacy assessment. Zebrafish at 2 dpf (days postfertilization) were treated with verapamil at a concentration of 200 μM for 30 min, which were determined as optimum conditions for model development. Tested drugs were administered into zebrafish either by direct soaking or circulation microinjection...
March 20, 2018: Zebrafish
https://www.readbyqxmd.com/read/29652187/blood-transfusion-during-total-ankle-arthroplasty-is-associated-with-increased-in-hospital-complications-and-costs
#7
Michael A Ewing, Samuel R Huntley, Dustin K Baker, Kenneth S Smith, Parke W Hudson, Gerald McGwin, Brent A Ponce, Michael D Johnson
INTRODUCTION: Total ankle arthroplasty (TAA) is an increasingly used, effective treatment for end-stage ankle arthritis. Although numerous studies have associated blood transfusion with complications following hip and knee arthroplasty, its effects following TAA are largely unknown. This study uses data from a large, nationally representative database to estimate the association between blood transfusion and inpatient complications and hospital costs following TAA. METHODS: Using the Nationwide Inpatient Sample (NIS) database from 2004 to 2014, 25 412 patients who underwent TAA were identified, with 286 (1...
April 1, 2018: Foot & Ankle Specialist
https://www.readbyqxmd.com/read/29652078/total-cardiovascular-events-analysis-of-the-examine-trial-in-patients-with-type-2-diabetes-and-recent-acute-coronary-syndrome
#8
Matthew A Cavender, William B White, Yuyin Liu, Joseph M Massaro, Richard M Bergenstal, Cyrus R Mehta, Faiez Zannad, Simon Heller, William C Cushman, Christopher P Cannon
BACKGROUND: Alogliptin, a dipeptidyl-peptidase 4 inhibitor, is approved for the treatment of patients with type 2 diabetes. EXAMINE was a randomized-controlled clinical trial designed to demonstrate the cardiovascular safety of alogliptin. In the trial, 5380 patients with established T2DM who had a recent ACS event (between 15-90 days) were randomized to treatment with either alogliptin or placebo. HYPOTHESIS: To better understand and describe the cardiovascular (CV) safety of alogliptin, we analyzed data from the EXAMINE randomized clinical trial to determine whether treatment with alogliptin affected recurrent and total CV events...
April 13, 2018: Clinical Cardiology
https://www.readbyqxmd.com/read/29651826/new-percutaneous-interventions-in-heart-failure
#9
Elisabetta Moscarella, Salvatore Brugaletta, Manel Sabaté
Chronic heart failure (HF) is one of the main causes of mortality and morbidity worldwide and represents a growing challenge in interventional cardiology. Its prevalence is recently increasing due to the improvements in cardiac care with subsequent significant reduction in the HF acute mortality. HF may occur with either a reduced left ventricular ejection fraction (LVEF) (LVEF<40%, HFrEF) or a preserved EF (typically LVEF≥50%, HFpEF) indicative of diastolic dysfunction. Despite recent advances in drug therapies as well as in nonpharmacological strategies, including defibrillators, cardiac resynchronization therapy, LV assist devices (LVAD), mortality in HF remains high...
April 12, 2018: Minerva Cardioangiologica
https://www.readbyqxmd.com/read/29650864/-a-case-of-home-care-for-heart-failure
#10
Haruhiko Tohyama
A female in her 80s with a history of cerebral infarction and atrial fibrillation had repeated hospitalizations because of heart failure caused by ischemic myocardiopathy. She lived alone and received home care and support for self-care with involvement of multiple providers, enabling early detection of disease exacerbation and subsequent intervention. A new ischemic event was managed with percutaneous coronary intervention. With deterioration of renal function, her response to diuretics decreased, and dialysis was initiated...
March 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29650709/machine-learning-methods-improve-prognostication-identify-clinically-distinct-phenotypes-and-detect-heterogeneity-in-response-to-therapy-in-a-large-cohort-of-heart-failure-patients
#11
Tariq Ahmad, Lars H Lund, Pooja Rao, Rohit Ghosh, Prashant Warier, Benjamin Vaccaro, Ulf Dahlström, Christopher M O'Connor, G Michael Felker, Nihar R Desai
BACKGROUND: Whereas heart failure (HF) is a complex clinical syndrome, conventional approaches to its management have treated it as a singular disease, leading to inadequate patient care and inefficient clinical trials. We hypothesized that applying advanced analytics to a large cohort of HF patients would improve prognostication of outcomes, identify distinct patient phenotypes, and detect heterogeneity in treatment response. METHODS AND RESULTS: The Swedish Heart Failure Registry is a nationwide registry collecting detailed demographic, clinical, laboratory, and medication data and linked to databases with outcome information...
April 12, 2018: Journal of the American Heart Association
https://www.readbyqxmd.com/read/29650239/lifestyle-therapy-for-the-management-of-atrial-fibrillation
#12
REVIEW
Ahmad A Abdul-Aziz, Mahmoud Altawil, Amanda Lyon, Mark MacEachern, Caroline R Richardson, Melvyn Rubenfire, Frank Pelosi, Elizabeth A Jackson
Atrial fibrillation (AF) is a common arrhythmia associated with increased risk of morbidity and mortality. There is evidence that lifestyle interventions may serve as complementary treatments to reduce AF burden. The objective of this review was to summarize the efficacy of lifestyle interventions for the management of AF. Studies which included patients with systolic heart failure (ejection fraction ≤40%), and those limited to an examination of vigorous physical activity were excluded from our search. Studies were identified through a search of the following databases: MEDLINE, EMBASE, CINAHIL, and PubMed, run from inception through August 2016...
February 7, 2018: American Journal of Cardiology
https://www.readbyqxmd.com/read/29650096/treatment-of-diabetes-in-people-with-heart-failure
#13
Kim A Connelly, Richard E Gilbert, Peter Liu
No abstract text is available yet for this article.
April 2018: Canadian Journal of Diabetes
https://www.readbyqxmd.com/read/29649151/dna-methylation-and-histone-modification-in-hypertension
#14
REVIEW
Shaunrick Stoll, Charles Wang, Hongyu Qiu
Systemic hypertension, which eventually results in heart failure, renal failure or stroke, is a common chronic human disorder that particularly affects elders. Although many signaling pathways involved in the development of hypertension have been reported over the past decades, which has led to the implementation of a wide variety of anti-hypertensive therapies, one half of all hypertensive patients still do not have their blood pressure controlled. The frontier in understanding the molecular mechanisms underlying hypertension has now advanced to the level of epigenomics...
April 12, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29648850/c-keith-conners-1933-2017
#15
Mark A Stein, Jeffrey H Newcorn
Presents an obituary of C. Keith Conners (1933-2017) who passed away of heart failure in Durham, North Carolina, on July 6, 2017. Conners was a pioneer in attention-deficit/hyperactivity disorder (ADHD) research and treatment. (PsycINFO Database Record
April 2018: American Psychologist
https://www.readbyqxmd.com/read/29648662/long-term-causes-of-death-in-patients-with-infective-endocarditis-who-undergo-medical-therapy-only-or-surgical-treatment-a-nationwide-population-based-study
#16
Lauge Østergaard, Louise Bruun Oestergaard, Trine Kiilerich Lauridsen, Anders Dahl, Mavish Chaudry, Gunnar Gislason, Christian Torp-Pedersen, Niels Eske Bruun, Nana Valeur, Lars Køber, Emil Loldrup Fosbøl
OBJECTIVES: It is known that patients surviving infective endocarditis have a poor long-term prognosis; however, few studies have addressed the long-term causes of death in patients surviving the initial hospitalization. METHODS: Using Danish administrative registries, we identified patients admitted to a hospital with 1st time infective endocarditis in the period from January 1996 to December 2014, who were alive at the time of discharge. The study population was categorized into (i) patients undergoing medical therapy only and (ii) patients undergoing surgical and medical treatment...
April 10, 2018: European Journal of Cardio-thoracic Surgery
https://www.readbyqxmd.com/read/29645278/an-evaluation-of-the-pharmacodynamics-safety-and-tolerability-of-the-potassium-binder-rdx7675
#17
Bertram Pitt, Vanessa Zann, Chris Roe, Jeffrey W Jacobs, James P Davidson, Christine Dowd, Padmapriya Kumaraswamy, Fangling Lin, Paul Korner, Robert C Blanks, David P Rosenbaum
Hyperkalemia is common in patients with heart failure or chronic kidney disease, particularly those taking renin-angiotensin-aldosterone system inhibitors, and can cause arrhythmias and sudden cardiac death. The most widely used treatment, sodium polystyrene sulfonate (SPS), limits gastrointestinal potassium absorption, but has poor palatability. RDX7675 (RDX227675) is the calcium salt of a reengineered polystyrene sulfonate-based resin with improved palatability over SPS. The pharmacodynamic effects and safety of RDX7675 were assessed in a phase 1, single-center, randomized, active-controlled study...
April 12, 2018: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29644505/cardiotoxicity-of-immunotherapy-incidence-diagnosis-and-management
#18
REVIEW
Aarti Asnani
PURPOSE OF REVIEW: This review describes cardiotoxicity associated with adoptive T cell therapy and immune checkpoint blockade. RECENT FINDINGS: Cardiotoxicity is a rare but potentially fatal complication associated with novel immunotherapies. Both affinity-enhanced and chimeric antigen receptor T cells have been reported to cause hypotension, arrhythmia, and left ventricular dysfunction, typically in the setting of cytokine release syndrome. Immune checkpoint inhibitors are generally well-tolerated but have the potential to cause myocarditis, with clinical presentations ranging from asymptomatic cardiac biomarker elevation to heart failure, arrhythmia, and cardiogenic shock...
April 11, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29644219/management-of-chemotherapy-induced-left-ventricular-dysfunction-and-heart-failure-in-patients-with-cancer-while-undergoing-cancer-treatment-the-md-anderson-practice
#19
Anecita P Fadol
Chemotherapy-induced cardiotoxicity resulting in heart failure (HF) is one of the most dreaded complications of cancer therapy that can significantly impact morbidity and mortality. With a high prevalence of cardiovascular disease in cancer patients, the risk of developing HF is significantly increased. A new discipline of Onco-Cardiology has evolved to address the cardiovascular needs of patients with cancer, however, there is limited evidence-based data to guide clinical decision-making in the management of the cardiovascular complications of cancer therapy...
2018: Frontiers in Cardiovascular Medicine
https://www.readbyqxmd.com/read/29643696/heart-regeneration-in-adult-mammals-after-myocardial-damage
#20
REVIEW
Baiping Cui, Yufan Zheng, Lihua Sun, Ting Shi, Ziyu Shi, Lijue Wang, Guoying Huang, Ning Sun
Heart regeneration remains a critical question in current basic research and clinical practice. The adult mammalian heart exhibits a very limited regeneration capacity. In contrast, adult zebrafish and neonatal mice retain a remarkable ability of heart regeneration after damage. Understanding the mechanisms of heart regeneration would be very valuable to help design efficient treatment strategies against myocardial damage and heart failure. While inherent regeneration of the heart occurs after damage with varying efficiency among species, regeneration may also be induced exogenously...
March 2018: Acta Cardiologica Sinica
keyword
keyword
112547
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"